PCM
OVID icon

Penserra Capital Management’s Ovid Therapeutics OVID Stock Holding History

Penserra Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,555
Closed -$5K – 1493
2021
Q3 		$5K Buy
1,555
+10
+0.6% +$36 ﹤0.01% 1409
2021
Q2 		$6K Buy
1,545
+105
+7% +$414 ﹤0.01% 1310
2021
Q1 		$5K Sell
1,440
-15
-1% -$50 ﹤0.01% 1088
2020
Q4 		$3K Buy
+1,455
New +$6.78K ﹤0.01% 991

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Penserra Capital Management's OVID Position: Q4 2021 in Review

Penserra Capital Management sold out of Ovid Therapeutics (OVID) in Q4 2021, closing a stake of 1,555 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in OVID in Q4 2020 and held it in 4 quarters. The position peaked at $6K in Q2 2021. 67 funds tracked by Wall St. Rank hold OVID as of Q4 2021.

  • Penserra Capital Management reported no remaining Ovid Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,555 Ovid Therapeutics shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Ovid Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Ovid Therapeutics position peaked at $6K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.